Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.

Soriano, J B; Vestbo, J; Pride, N B; Kiri, V; Maden, C; Maier, W C

Soriano, J B; Vestbo, J; Pride, N B; Kiri, V; Maden, C; Maier, W C.

Affiliation

Soriano JB; Worldwide Epidemiology Dept, GlaxoSmithKline Research and Development, Greenford, Middlesex, UK. joan.b.soriano@gsk.com

Eur Respir J ; 20(4): 819-25, 2002 Oct.

Article in En | MEDLINE | ID: mdl-12412670

Subject(s)

Albuterol/analogs & derivatives; Albuterol/administration & dosage; Androstadienes/administration & dosage; Anti-Inflammatory Agents/administration & dosage; Pulmonary Disease, Chronic Obstructive/drug therapy; Pulmonary Disease, Chronic Obstructive/mortality; Administration, Inhalation; Aged; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Family Practice/methods; Female; Fluticasone; Humans; Male; Middle Aged; Probability; Prognosis; Pulmonary Disease, Chronic Obstructive/diagnosis; Reference Values; Respiratory Function Tests; Retrospective Studies; Salmeterol Xinafoate; Survival Analysis; Treatment Outcome; United Kingdom

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / Albuterol / Androstadienes / Anti-Inflammatory Agents Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Eur Respir J Year: 2002 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links